Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Mechanistic Systems Modeling to Improve Understanding and Prediction of Cardiotoxicity Caused by Targeted Cancer Therapeutics.

Shim JV, Chun B, van Hasselt JGC, Birtwistle MR, Saucerman JJ, Sobie EA.

Front Physiol. 2017 Sep 8;8:651. doi: 10.3389/fphys.2017.00651. eCollection 2017.

2.

Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.

Aghel N, Delgado DH, Lipton JH.

Vasc Health Risk Manag. 2017 Aug 4;13:293-303. doi: 10.2147/VHRM.S108874. eCollection 2017. Review.

3.

Cancer and Heart Failure: Understanding the Intersection.

Hamo CE, Bloom MW.

Card Fail Rev. 2017 Apr;3(1):66-70. doi: 10.15420/cfr.2016:24:2.

4.

Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.

Hurtado-de-Mendoza D, Loaiza-Bonilla A, Bonilla-Reyes PA, Tinoco G, Alcorta R.

Cureus. 2017 May 18;9(5):e1258. doi: 10.7759/cureus.1258. Review.

5.

c-Abl regulates gastrointestinal muscularis propria homeostasis via ERKs.

Xiang J, Zhang Y, Bao D, Cao N, Zhang X, Li P, Qiu S, Guo J, He D, Li B, Yao L, Liu H.

Sci Rep. 2017 Jun 15;7(1):3563. doi: 10.1038/s41598-017-03569-0.

6.

The cancer theory of pulmonary arterial hypertension.

Boucherat O, Vitry G, Trinh I, Paulin R, Provencher S, Bonnet S.

Pulm Circ. 2017 Apr-Jun;7(2):285-299. doi: 10.1177/2045893217701438. Epub 2017 Mar 27.

7.

Imatinib attenuates cardiac fibrosis by inhibiting platelet-derived growth factor receptors activation in isoproterenol induced model.

Wang LX, Yang X, Yue Y, Fan T, Hou J, Chen GX, Liang MY, Wu ZK.

PLoS One. 2017 Jun 1;12(6):e0178619. doi: 10.1371/journal.pone.0178619. eCollection 2017.

8.

Tyrosine kinase-targeting drugs-associated heart failure.

Gronich N, Lavi I, Barnett-Griness O, Saliba W, Abernethy DR, Rennert G.

Br J Cancer. 2017 May 9;116(10):1366-1373. doi: 10.1038/bjc.2017.88. Epub 2017 Apr 11.

PMID:
28399109
9.

Imatinib and spironolactone suppress hepcidin expression.

Mleczko-Sanecka K, da Silva AR, Call D, Neves J, Schmeer N, Damm G, Seehofer D, Muckenthaler MU.

Haematologica. 2017 Jul;102(7):1173-1184. doi: 10.3324/haematol.2016.162917. Epub 2017 Apr 6.

10.

AMP-activated protein kinase and energy balance in breast cancer.

Zhao H, Orhan YC, Zha X, Esencan E, Chatterton RT, Bulun SE.

Am J Transl Res. 2017 Feb 15;9(2):197-213. eCollection 2017. Review.

11.

Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells.

Li Q, Huang Z, Gao M, Cao W, Xiao Q, Luo H, Feng W.

Int J Mol Sci. 2017 Mar 2;18(3). pii: E537. doi: 10.3390/ijms18030537.

12.

Imatinib increases oxygen delivery in extracellular matrix-rich but not in matrix-poor experimental carcinoma.

Burmakin M, van Wieringen T, Olsson PO, Stuhr L, Åhgren A, Heldin CH, Reed RK, Rubin K, Hellberg C.

J Transl Med. 2017 Feb 23;15(1):47. doi: 10.1186/s12967-017-1142-7.

13.

High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.

Sharma A, Burridge PW, McKeithan WL, Serrano R, Shukla P, Sayed N, Churko JM, Kitani T, Wu H, Holmström A, Matsa E, Zhang Y, Kumar A, Fan AC, Del Álamo JC, Wu SM, Moslehi JJ, Mercola M, Wu JC.

Sci Transl Med. 2017 Feb 15;9(377). pii: eaaf2584. doi: 10.1126/scitranslmed.aaf2584.

14.

Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics.

Patras de Campaigno E, Bondon-Guitton E, Laurent G, Montastruc F, Montastruc JL, Lapeyre-Mestre M, Despas F.

Br J Clin Pharmacol. 2017 Jul;83(7):1544-1555. doi: 10.1111/bcp.13238. Epub 2017 Feb 14.

PMID:
28098949
15.

Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.

Rausch JL, Boichuk S, Ali AA, Patil SS, Liu L, Lee DM, Brown MF, Makielski KR, Liu Y, Taguchi T, Kuan SF, Duensing A.

Oncotarget. 2017 Jan 17;8(3):4471-4483. doi: 10.18632/oncotarget.13882.

16.

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.

Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, Van Etten RA.

Haematologica. 2017 Mar;102(3):519-528. doi: 10.3324/haematol.2016.152710. Epub 2016 Dec 7.

17.

Sildenafil attenuates hypoxic pulmonary remodelling by inhibiting bone marrow progenitor cells.

Favre S, Gambini E, Nigro P, Scopece A, Bianciardi P, Caretti A, Pompilio G, Corno AF, Vassalli G, von Segesser LK, Samaja M, Milano G.

J Cell Mol Med. 2017 May;21(5):871-880. doi: 10.1111/jcmm.13026. Epub 2016 Nov 18.

18.

Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?

Magdy T, Burmeister BT, Burridge PW.

Pharmacol Ther. 2016 Dec;168:113-125. doi: 10.1016/j.pharmthera.2016.09.009. Epub 2016 Sep 5. Review.

19.

PDGFRα signalling promotes fibrogenic responses in collagen-producing cells in Duchenne muscular dystrophy.

Ieronimakis N, Hays A, Prasad A, Janebodin K, Duffield JS, Reyes M.

J Pathol. 2016 Dec;240(4):410-424. doi: 10.1002/path.4801. Epub 2016 Oct 20.

20.

Oncocardiology-Past, Present, and Future: A Review.

Yeh ET, Chang HM.

JAMA Cardiol. 2016 Dec 1;1(9):1066-1072. doi: 10.1001/jamacardio.2016.2132.

Supplemental Content

Support Center